CTOs on the Move


 
Kyros is committed to breaking down barriers, creating a community of support, and making a lasting impact on the lives of those affected by SUD. Through innovative training models, compassionate peer support, and a focus on human-centered solutions, Kyros strives to redefine recovery and provide hope for a healthier future. Founded in 2021 by Daniel Larson, after he encountered obstacles in his own journey with substance use disorder, Kyros` mission is to increase positive outcomes for the millions of Americans managing their own recovery or dedicating their lives to help others find support and wellbeing.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kyros.care
  • 401 2nd Avenue North Suite 500
    Minneapolis, MN USA 55401
  • Phone: 612.900.2233

Executives

Name Title Contact Details

Similar Companies

Destination Pet

Welcome to your destination. Our mission is simple: to provide the best for your pet.

Registered Practical Nurses Association of Ontario

Registered Practical Nurses Association of Ontario is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Westlake Medical Research

Westlake Medical Research is a Westlake Village, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meta Dental Co

Meta Dental Co is a Elmhurst, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nanoscope Therapeutics

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.